Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria DNA vaccine - Okairos AG

Drug Profile

Malaria DNA vaccine - Okairos AG

Alternative Names: AdCh63 ME-TRAP - Okairos AG; ChAd63 ME-TRAP - Okairos AG; ME-TRAP malaria DNA vaccine - Okairos AG/University of Oxford; MVA ME-TRAP - Okairos AG

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Okairos AG
  • Developer Okairos AG; University of Oxford
  • Class Antimalarials; DNA vaccines; Parasitic vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 10 Sep 2018 Discontinued - Phase-II for Malaria (Prevention) in Senegal, United Kingdom, Kenya, Burkina Faso (IM)
  • 09 Sep 2015 Phase-I/II development is ongoing in Burkina Faso
  • 09 Sep 2015 Phase-II development is ongoing in United Kingdom, Kenya and Senegal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top